ast February, Northwest Biotherapeutics (NWBO), the Maryland-based company developing an experimental brain cancer treatment called DCVax, said that it had collected enough clinical trial data to determine whether its vaccine could delay the growth of tumors longer than standard of care.

In other words, the randomized, controlled study was ready to be analyzed.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.